Dublin, Aug. 17, 2017 -- The "Cell-Free DNA (cfDNA): Market Size and Share Analysis" report has been added to Research and Markets' offering.
The use of cell-free DNA (cfDNA) and liquid biopsies of other analytes has received a huge amount of attention in recent years, due to its potential to revolutionize the diagnosis and treatment of several conditions. The main areas where cfDNA analysis has turned into a major application include non-invasive prenatal testing (NIPT); oncology, circulating tumor DNA (ctDNA); and transplantation, donor-derived cell-free DNA (ddcfDNA).
Cell-Free DNA (cfDNA) Markets focuses on the market for cfDNA analysis instruments, consumables, kits, and related software, which includes the sample preparation products and equipment as well as the next generation sequencing (NGS) and digital polymerase chain reaction (dPCR) systems used for detection.
The report provides complete market information, including current market estimates and forecasts to 2021, as well as:
- Growth Rate for cfDNA Market, 2016-2021
- cfDNA Clinical Diagnostics Market, 2016-2021
- cfDNA Clinical Diagnostics Market Growth Rate, 2016-2021
- cfDNA Market by Region, 2015 (N. America, Europe, Asia-Pacific & ROW)
- cfDNA Instruments and Consumables Revenues by Product Type, 2016 (Consumables, Systems/hardware, Services)
- Market Share by Company of the cfDNA Analysis Instruments, Consumables, and Software Market, 2016
The report provides information on cfDNA analysis products, commenting not only on reagents, consumables, kits, systems, software, and services, but also on oncology cfDNA products, cfDNA transplantation diagnostics, and other products employing cfDNA.
In the cfDNA market there are many technical challenges to overcome, along with a range of competitive, regulatory, and IP issues. Cancer is a dynamic and defiant disease. While NIPT is a proven application, oncology will require much more difficult work and is more uncertain. The variety of potential issues and threats in the market are covered in the challenges and strategic recommendations chapter of the report. The competitive situation, deals, and litigation are covered in respective chapters as well.
Cell-Free DNA (cfDNA) Markets covers not just the dynamics of the market but also its competitive landscape. For example, several companies are licensing their technologies or offering services.
The report profiles those companies competing in the cfDNA instruments and consumables market, including:
- Agilent Technologies
- Bio-Rad
- F. Hoffmann-La Roche AG
- Fluidigm
- Illumina
- Qiagen
- RainDance Technologies
- Thermo Fisher Scientific
Key Topics Covered:
1: Executive Summary
- NIPT, Oncology Leading Market Forward
- Sensitivity Benefits of dPCR, qPCR, NGS
- Challenges, Biological and Technologies Limitations
- Scope and Methodology
2: Introduction
- NIPT Companies, Others Shifting Strategies to Cancer
- Expanding Clinical Adoption Sustains High Growth
- Government Initiatives - Cancer Moonshot, Blood Profiling Atlas
- Mergers, Acquisitions, Equity Investments Increasing
- China Becoming Major Player in Market
- Personalized, Proactive Medicine Gaining Momentum
- Expected Sequencer Platforms Stalled or Cancelled
- Significant Efforts in Automation, Miniaturization
- Regulatory Situation Unclear But Evolving Somewhat
3: CFDNA PRODUCTS
- cfDNA Reagents, Consumables, and Kits
- cfDNA Systems and Software
- cfDNA NIPT Products and Services
- cfDNA in Oncology, Transplantation and Other Diseases
- cfDNA Other Products
- Recent Product/ Service Introductions
4: Market Size And Share Analysis
- Revenues Forecast
- Market Size and Forecast
- cfDNA Clinical Diagnostics Market
- cfDNA Market by Region
- Revenues by Product Type
- Illumina Sequencing Revenues as Indicator
5: Corporate Profiles
- Agilent Technologies
- F. Hoffmann-La Roche AG
- Fluidigm
- Illumina
- Qiagen
- RainDance Technologies
- Thermo Fisher Scientific
6: Challenges and Strategic Recommendations
- Challenges
- Strategic Recommendations
- List of Exhibits
7: cfDNA Analysis Products
8: Market Analysis
9: cfDNA Analysis Market Deals
For more information about this report visit https://www.researchandmarkets.com/research/wtghlt/cellfree_dna
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Genomics


Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 



